Search clinical trials for: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Total 290113 results

Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Australia, China, Korea, Republic of, Taiwan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Non Small Cell Lung Cancer

China
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Dizal Pharmaceuticals

Not yet recruiting

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (JACKPOT33)

Non-Small-Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Scorpion Therapeutics, Inc.

Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Non-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion Mutation

United States, Taiwan
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Non-Small Cell Lung Cancer

China
Teligene US

Recruiting

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

United States
Akeso

Not yet recruiting

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Nasopharyngeal Carcinoma | Non-small Cell Lung Cancer

China
Genentech, Inc.

Recruiting

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Colorectal Cancer | Non-Small Cell Lung Cancer

Korea, Republic of, Australia, Canada, United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Centre Georges Francois Leclerc

Not yet recruiting

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK)

Non-Small Cell Lung Cancer
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
Fog Pharmaceuticals, Inc.

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer | Gastric Cancer | Colorectal Cancer | Solid Tumor | Metastatic Cancer | Adenomatous Polyposis Coli | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Carcinoma | Locally Advanced Solid Tumor | Non-small Cell Lung Cancer Stage IIIB | Gastroesophageal-junction Cancer | Non-Small... and other conditions

United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | RC48 | Disitamab Vedotin

China
Beijing Biostar Pharmaceuticals Co., Ltd.

Recruiting

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, China
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK-IGR)

Non Small Cell Lung Cancer | KRAS P.G12C

France
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL845 in Adults With Solid Tumors

Melanoma | Colorectal Cancer | Non-small Cell Lung Cancer

United States
RedCloud Bio
R&G Pharma Studies Co.,Ltd.

Recruiting

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
Fudan University
Allist Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Non-Small-Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Locally Advanced or Metastatic Solid Tumor

China
Teligene US

Recruiting

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
Institut Cancerologie de l'Ouest

Recruiting

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy (TRAILOCLORI01)

Metastatic Non Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer

France
Shanghai Henlius Biotech

Recruiting

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Non-small Cell Lung Cancer | Locally Advanced or Metastatic Solid Tumors

Australia
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Hutchison Medipharma Limited

Recruiting

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (SANOVO)

Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China

Search clinical trials for: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations